The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams.EBI
Merck Sharp & Dohme Research Laboratories
Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin.EBI
Centre De Pharmacologie-Endocrinologie (Montpellier, France)
Synthesis and biological activity of CCK26-33-related analogues modified in position 31.EBI
University of Paris
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.EBI
Merck Sharp & Dohme Research Laboratories
Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.EBI
TBA
Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors.EBI
TBA
Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.EBI
TBA
Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.EBI
Mayo Clinic
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.EBI
Merck Sharp & Dohme Research Laboratories
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.EBI
TBA
 
Conversion of acyclic nonpeptide CCK antagonists into CCK agonistsEBI
Glaxo Wellcome Research and Development
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.EBI
Predix Pharmaceuticals
A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.EBI
Mayo Clinic and Foundation
Investigation of peripheral cholecystokinin receptor heterogeneity by cyclic and related linear analogues of CCK26-33: synthesis and biological properties.EBI
TBA
Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.EBI
Abbott Laboratories
N-methylated analogs of Ac[Nle28,31]CCK(26-33): synthesis, activity, and receptor selectivity.EBI
Hadassah-University Hospital